Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate

Journal of Infectious Diseases

Volumn 186, Issue 1, 2002, Pages 138-140

  Rodriguez, Noris ^a,c   Bailey, Brian N ^a   Martin, Michael B ^b   Oldfield, Eric ^b   Urbina, Julio A ^a,d   Docampo, Roberto ^a  

^a Department of Pathobiology   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c INSTITUTO DE BIOMEDICINA   (Venezuela)

^d INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; KINETOPLAST; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; OSTEOCLAST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTOZOAL INFECTION; SKIN LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DNA, KINETOPLAST; INJECTIONS, INTRAPERITONEAL; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; STAINING AND LABELING;

EID: 0036642486     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/341074     Document Type: Article

References (12)

1. Clinical and experimental advances in treatment of visceral leishmaniasis
2. Bisphosphonates as chemotherapeutic agents against trypanosomatid and apicomplexan parasites
3. Therapeutic approaches to bone diseases
4. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase
5. 2+pool content and signaling and expression of a calcium pump are linked to virulence in Leishmania mexicana amazonensis amastigotes
6. Diagnosis of cutaneous leishmaniasis and species discrimination of parasites by PCR and hybridization
7. Identification and diagnosis of Leishmania mexicana complex isolates by polymerase chain reaction
8. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis
9. γ/δ T-cell stimulation by pamidronate
10. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse
11. Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) in rats and mice
12. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy